PHVS Stock Pharvaris N.V.
US · NasdaqGSLast in our picks 2026-10-24 — not in the current list; analysis below is from that screen
Rare-disease therapy catalysts offer asymmetric value if development milestones remain favorable.
Future value: $57.78 (+83.96%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Multiple analysts maintain buy ratings with targets materially above market.
- ▾Below 50-day MA (-7.56%)
- ▸Above 200-day MA — long-term uptrend
- ▸~84% upside to price target
Is PHVS a buy right now?
Trend: PHVS is trading below the 50-day average (-6.61%), RSI 52 — neutral momentum, with a 3-month return of -5.87%.
Valuation & quality: Pharvaris N.V. trades on forward P/E -10.4, price-to-book 6.58; fundamentals show net margin 0.0%, return on equity -70.5%.
Analyst consensus: 14 analysts have a mean 12-month price target of $57.58 (+81.8% vs the last close; range $40.95 – $78.90), consensus rating “strong buy”.
Our screen: STRONG BUY (score 4) — Rare-disease therapy catalysts offer asymmetric value if development milestones remain favorable.
Computed from end-of-day data; not personal advice.
Our track record with PHVS
First flagged in our daily picks as BUY on 2026-10-22 at $30.66 — +3.3% since. It has appeared in the picks on 3 days.
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -0.50% | +9.80% | -2.70% | +14.70% | -5.70% | +6.10% | -8.40% | -0.20% |
Fundamentals
Analyst price target
Technical signals
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Sector: Healthcare · Industry: Biotechnology · Switzerland · 148 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.